Skip to main content

An innovative bio-based platform for the cost-competitive production of L-fucose, a building block for Human Milk Oligosaccharides (HMOs).

Periodic Reporting for period 2 - FucoPol (An innovative bio-based platform for the cost-competitive production of L-fucose, a building blockfor Human Milk Oligosaccharides (HMOs).)

Reporting period: 2018-10-01 to 2019-09-30

Currently a large scale production of HMOs is not feasible due to the complexity and costs related to increasing availability of L-fucose. 73100 has developed and patented a novel bacterial biopolymer - FucoPol - as a natural source for the efficient and cost-competitive production of pure L-fucose. The main objective of the project is to demonstrate and validate the scalability of the platform, proving its usefulness for industrial-scale production.
The Fermentation Pilot Production at Biotrend for the 1st 10L and 200L Fermentation trials were successfully completed during the first year of the Phase 2 project. The work discussion with Cipan for 1m3 scale-up started in July 2018, after the conclusion of the Biotrend 200 L trial, were interrupted during the August summer break, and resumed in September towards the detailed planning. The technical discussion and planning for the large scale-up step is ongoing.
The Regulatory assessment for Fucose was successfully completed. It is important to mention that the EFSA regulation laws on novel Food changed in March 2018. The company Nutrition Consultants Cooperative (NCC) was contracted, and the first consultation was already made. They suggested to submit the Consultation Request for Determination of the Novel Food Status of L-Fucose to EFSA. The Consultation request was completed in October 2018 and has been submitted to EFSA.
Commercial activities during year 1, included several iterations of market intelligence performed by the team. Commercial activities also included the preparation of the participation in CPhI 2018, although the event took place in October 2018, so formally in Year 2 of the project. The commercialization plan was prepared, which got several inputs with the aid of the SME Instrument coaching service. The commercialization plan will be put into action during Year 2.
73100 is set to become the world’s first large scale L-fucose producer. Current technologies are hindered by the complexity and costs related to the attempt to increase the availability of the core component, L-fucose. The innovative technology – on which the FucoPol production is based – entails its use as a natural platform to generate pure carbohydrates (fucose, galactose, glucose and glucuronic acid), either in mixtures with defined composition or as individual monosaccharides. Depending on the application of L-fucose, 73100 has the potential to sell to several different customer types. 73100 have identified the most desired applications for FucoPol derived products, mainly L-fucose, and have identified companies engaged in chemical synthesis for HMO’s, manufacturing of prebiotic food/beverages, pharmaceuticals, and cosmetics. 73100 has the potential to first sell to chemical reagent distributors in Europe and North America. 73100 expects rapid growth once commercialized and increased profitability as their product is sold for new HMO applications (e.g. as a novel food ingredient). 73100 also has the potential to address relevant challenges faced by many European societies – mainly related to providing an adequate supply for high-quality food while enhancing innovation and sustainability in the production processes. In fact, glycoscience in Europe is fast becoming an essential part of modern innovative biotechnology and having access to state-of-the-art knowledge and technologies in this sector will provide the European bio-based industries with a strong competitive advantage on a worldwide stage.
FucoPol Scale-up
FucoPol Fermentation
CPhi 2018